Actively Recruiting
Effect of EA-230 on Hospital Stay Duration in Coronary Artery Disease Patients Undergoing Bypass Surgery
Led by EBI Anti Sepsis BV · Updated on 2026-11-02
300
Participants Needed
6
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the potential of EA-230, a new therapy, to help patients recover faster and experience fewer complications after Coronary Artery Bypass Grafting CABG surgery for Coronary Artery Disease CAD. This Phase III trial is designed to confirm earlier findings that EA-230 was safe and reduced hospital and ICU stays compared to a placebo. The study is randomized, double-blind, and placebo-controlled to ensure unbiased results. Participants will receive either EA-230 or a placebo intravenously at a dose of 90 mgkg per hour for 4 hours during surgery. The trial includes multiple visits a screening visit, a pre-operative visit, 7 hospital visits during the stay, and 2 remote visits, totaling 10 visits over about 71 days. The study compares hospital length of stay and other post-surgery recovery measures. During participation, patients will undergo various assessments including monitoring of hospital and ICU stay durations, hemodynamic stability, and blood plasma levels of EA-230 shortly after administration. Safety evaluations will also be conducted up to 28 days post-surgery. Overall, participants will be followed for approximately 71 days to capture recovery outcomes and safety data.
CONDITIONS
Brief Title
A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.
Research Team
B
Bas Ossenkoppele, Msc
L
Leonie Koomen, Msc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here